<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background </plain></SENT>
<SENT sid="1" pm="."><plain>This study was aimed at comparing <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, seen as microvessel density (MVD) in subtypes of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) </plain></SENT>
<SENT sid="2" pm="."><plain>Methods </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, 64 cases of NHL diagnosed over a three-year period were included along with 15 lymph node biopsies of reactive <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>NHLs were classified using REAL classification, and immunohistochemistry was performed for CD34 in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="5" pm="."><plain>CD34-stained sections were evaluated for "hot spots," where MVD was assessed and expressed as per mm(2) </plain></SENT>
<SENT sid="6" pm="."><plain>Appropriate statistical methods were applied </plain></SENT>
<SENT sid="7" pm="."><plain>Results </plain></SENT>
<SENT sid="8" pm="."><plain>There were 6 cases of well-differentiated lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>), 21 diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), 15 follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 10 lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 7 MALToma, and 5 peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e>) </plain></SENT>
<SENT sid="9" pm="."><plain>Mean MVD was highest in reactive <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> (191.92 ± 12.16 per mm(2)) compared to <z:hpo ids='HP_0000001'>all</z:hpo> NHLs </plain></SENT>
<SENT sid="10" pm="."><plain>Among NHLs, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e> demonstrated the highest MVD (183.42 ± 8.24) followed by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (149.91 ± 13.68) </plain></SENT>
<SENT sid="11" pm="."><plain>A significant difference was found in MVD between reactive and individual <z:hpo ids='HP_0002665'>lymphoma</z:hpo> groups </plain></SENT>
<SENT sid="12" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e> had significantly lower MVD than other <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes </plain></SENT>
<SENT sid="13" pm="."><plain>Conclusion </plain></SENT>
<SENT sid="14" pm="."><plain><z:mpath ids='MPATH_177'>Angiogenesis</z:mpath>, assessed by MVD, showed significant differences among subtypes of NHL, especially the indolent types like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>The higher MVD in aggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> can potentially be utilized in targeted therapy with antiangiogenic drugs </plain></SENT>
</text></document>